Molecular Determinants of Decitabine Response

地西他滨反应的分子决定因素

• 批准号: 8595785
• 负责人: TIMOTHY J. LEY
• 金额: $ 33.05万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-03 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8595785
• 关键词: Acute Myelocytic Leukemia; Affect; Azacitidine; Base Sequence; Biological Markers; Blast Cell; Bone Marrow; Clinical; Clinical assessments; Consent; Custom; DNA Methylation; Data; Decitabine; Disease; Disease-Free Survival; Dose; Dysmyelopoietic Syndromes; Frequencies; Gene Frequency; Gene Mutation; Gene Silencing; Genes; Genie; Genome; Genomics; Genotype; Goals; In complete remission; Instruction; Malignant Neoplasms; Marrow; Mass Spectrum Analysis; Measurement; Measures; Messenger RNA; Metabolism; MicroRNAs; Molecular; Molecular Profiling; Mutate; Mutation; Nature; Oligonucleotides; Outcome; Outpatients; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacodynamics; Protocols documentation; Research; Resistance; Sampling; Schedule; Sequence Analysis; Serum; Somatic Mutation; Stem cell transplant; Time; Tumor Burden; base; clinical decision-making; digital; drug metabolism; exome; exome sequencing; leukemia; molecular marker; mutant; overexpression; programs; response

The long term goal of this project is to identify the patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who are the most likely to respond to decitabine therapy. Decitabine is a hypomethylating agent that has efficacy in both MDS and AML. It can be given as an outpatient, and it is well tolerated in most patients. However, response rates are modest; even with modern aggressive schedules, only 4 5 % of patients achieve a complete response. The molecular basis of decitabine sensitivity and/or resistance is not yet clear. Specific Aims: Aim1.Wewilldefinethemolecularsignatureofdecitabineresponders.Wewillprospectivelybank125 properly consented patients treated with the current state-of-the-art decitabine protocol. We will comprehensively define patient-specific molecular signatures through exome sequencing and expression profiling, using both mRNA and miRNA based arrays. We will correlate genotyping and expression results with clinical features, including responsiveness to decitabine therapy. These studies will correlate genomic signatures of DNMT3A, I D H I , IDH2, and TET2 with outcomes. In addition, comprehensive, unbiased analysis will determine whether specific molecular signatures are associated with decitabine responses. Aim 2. We will determine whether the rate of AML clearance and persistence of AML-associated subclones corresponds tddrug metabolism, molecular, and/or clinical features of AML in each case. We will assess the velocity of patient-specific mutation clearance on day 0, 10, and 28, and the persistence of AML-associated subclones despite blast clearance. W e will correlate this with steiady-state decitabine drug levels, the reduction of methylcytosine in the total marrow sample (a biomarker of effective dosing), and with clinical response rates and event-free survival. RELEVANCE (See instructions): Many patients do not respond to decitabine therapy for AML or MDS. The causes of sensitivity and resistance are unknown. In this study we will optimize a pipeline for comprehensive molecular characterization of patient-specific mutations, expression profiles, and pharmacologic outcomes. We will determine whether molecular signatures predict response or resistance to decitabine.

本项目的长期目标是鉴别急性髓性白血病（AML）患者和